This Hot Biotech Stock Just Set New All-Time Highs

Core Insights - BridgeBio Pharma (BBIO) is valued at $13.8 billion and focuses on discovering, developing, and innovating drugs for genetic diseases [1] - The company has a strong technical profile with a 100% "Buy" opinion from Barchart and has surged 145% over the past year [6][7] - Revenue is projected to grow significantly, with a 123% increase expected this year and a further 79.63% next year [6][7] Company Overview - BridgeBio Pharma specializes in Mendelian, oncology, and gene therapies, with a product pipeline that includes BBP-265, BBP-831, and BBP-454 in various clinical stages [1] - The stock recently traded at $70.96, with a 50-day moving average of $62.84, and has reached an all-time high of $75.10 on December 8 [4][7] Technical Analysis - BBIO has gained 29.85% since a new "Buy" signal was issued on October 6 [2] - The stock has made 12 new highs and gained 13.02% in the last month, with a Relative Strength Index (RSI) of 58.32 [7] - There is a technical support level around $70.52 [7] Financial Projections - Revenue is expected to grow by 123% this year and 79.63% next year, while earnings are estimated to decrease by 61.11% this year before rebounding by 44.41% next year [6][8]